Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Commercial preparations accompany higher expenses, while Cogent expects its cash resources to fund operations into late 2028.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cogent Biosciences (Nasdaq: COGT) reported third-quarter 2026 results while preparing for a potential bezuclastinib launch in gastrointestinal stromal tumors (GIST). FDA target action dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvanced Systemic Mastocytosis and June 29, 2027 for Advanced Systemic Mastocytosis. The FDA accepted the application for the advanced disease indication.
Cash, cash equivalents and marketable securities totaled $791.1 million at September 30, versus $792.3 million at June 30; Cogent expects funding to last into late 2028. Quarterly net loss widened to $111.426 million from $80.930 million a year earlier, with research and administrative expenses rising. Cogent initiated a 40-patient first-line GIST extension cohort and plans investigational drug applications for CGT1815 and CGT1145 in Q4 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cogent expects $791.1 million in cash resources to fund operations into late 2028.
- Minor pointBezuclastinib’s Advanced Systemic Mastocytosis application received FDA acceptance.
- Minor pointCommercial team is in place for the anticipated bezuclastinib GIST launch.
- Minor pointPEAK trial expansion initiated a 40-patient cohort studying first-line GIST treatment.
- Minor point. Forward-looking: it has not happened yet and may not happen.Cogent plans Q4 2026 investigational drug applications for CGT1815 and CGT1145.
4 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.CGT4255 development plans include completing dose escalation.
- Minor pointQuarterly interest income rose to $7.052 million from $3.887 million a year earlier.
- Minor pointNine-month interest income rose to $22.121 million from $9.212 million a year earlier.
- Minor pointQuarterly interest expense fell to $1.243 million from $1.459 million a year earlier.
Negative
- Moderate pointQuarterly net loss widened to $111.426 million from $80.930 million a year earlier.
- Moderate pointQuarterly research and development expenses increased to $75.099 million from $68.989 million a year earlier.
- Moderate pointQuarterly general and administrative expenses increased to $42.085 million from $14.366 million a year earlier.
- Moderate pointBezuclastinib approvals remain pending, with FDA target action dates spanning November 2026 through June 2027.
- Minor pointNine-month net loss widened to $305.183 million from $226.445 million a year earlier.
10 minor points
- Minor pointNine-month research and development expenses increased to $221.275 million from $194.221 million a year earlier.
- Minor pointNine-month general and administrative expenses increased to $102.154 million from $39.649 million a year earlier.
- Minor pointCash resources declined to $791.1 million at September 30, 2026, from $792.3 million at June 30.
- Minor pointWorking capital fell to $730.466 million at September 30, 2026, from $846.402 million at December 31, 2025.
- Minor pointTotal assets fell to $832.142 million at September 30, 2026, from $937.607 million at December 31, 2025.
- Minor pointTotal liabilities rose to $315.884 million at September 30, 2026, from $301.236 million at December 31, 2025.
- Minor pointStockholders’ equity fell to $516.258 million at September 30, 2026, from $636.371 million at December 31, 2025.
- Minor pointNine-month interest expense increased to $3.673 million from $1.773 million a year earlier.
- Minor pointQuarterly other expense, net, increased to $51,000 from $3,000 a year earlier.
- Minor pointNine-month other expense, net, increased to $202,000 from $14,000 a year earlier.
News Explained
At the
Key Figures
- Cash, cash equivalents and marketable securities
- $791.1 million
- As of September 30, 2026; expected to fund operations into late 2028
- R&D expenses
- $75.1 million
- Q3 2026, vs. $69.0 million in Q3 2025
- G&A expenses
- $42.1 million
- Q3 2026, vs. $14.4 million in Q3 2025
- Net loss
- $111.4 million
- Q3 2026, vs. $80.9 million in Q3 2025
- GIST PDUFA action date
- November 30, 2026
- Potential bezuclastinib FDA approval
- NonAdvSM PDUFA action date
- December 30, 2026
- Potential bezuclastinib FDA approval
- AdvSM PDUFA action date
- June 29, 2027
- Potential bezuclastinib FDA approval
- PEAK extension cohort
- 40 patients
- Single-arm cohort investigating bezuclastinib with sunitinib in first-line GIST
Previous Earnings Reports
-
Q2 reported $792.3 million cash and expected operations funding into late 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pdufa regulatory
new drug application regulatory
orr medical
pfs medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026
NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date
June 29, 2027
Cash balance of
WALTHAM, Mass. and BOULDER, Colo., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.
“With our commercial team in place, we are prepared to execute on the anticipated launch of bezuclastinib in GIST,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “In parallel, our team is preparing for potential approvals in NonAdvanced and Advanced Systemic Mastocytosis and we expect to file INDs for our JAK2 and KRAS pipeline programs this quarter. Backed by a strong balance sheet and a world-class team, we are well positioned to continue our vision of creating best-in-class therapies for patients fighting rare, mutationally driven diseases.”
Business Highlights
- Plan to present multiple posters featuring bezuclastinib at the 68th Annual Meeting of the American Society of Hematology (ASH) being held December 12-15, 2026, in New Orleans. Featured results will highlight more detailed analyses from the SUMMIT trial of bezuclastinib’s effects on skin and neurocognitive symptoms, longer term pathobiology follow-up and an MS2D2 symptomatic comparison of symptom burden in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients before and after bezuclastinib treatment with that of the general population. Included in these presentations will be the first look at clinical results from the SUMMIT sub-study, investigating the patient benefit of switching from avapritinib to bezuclastinib.
- Announced the initiation of a single-arm, 40 patient extension cohort of the PEAK trial investigating the safety and efficacy of bezuclastinib in combination with sunitinib in first-line GIST patients. This cohort is designed to prospectively measure ORR and PFS in patients with either exon 9 or exon 11 primary mutations.
- Announced the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM).
Anticipated Upcoming Milestones
- Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026
- Potential FDA approval of bezuclastinib in NonAdvSM – PDUFA date of December 30, 2026
- Potential FDA approval of bezuclastinib in AdvSM – PDUFA date of June 29, 2027
- Investigational New Drug (IND) applications to be submitted for CGT1815, Cogent’s novel, selective pan-KRAS(ON) inhibitor, and CGT1145, Cogent’s novel, selective JAK2 V617F inhibitor in Q4 2026
- Complete dose escalation for CGT4255, Cogent’s CNS-penetrant, selective mutant ErbB2 inhibitor
Upcoming Investor Conferences
- Guggenheim Healthcare Innovation Conference on November 10 at 7:30 am ET
- UBS Global Biopharma Conference on November 17 at 12:00 pm GMT (7:00 am ET)
- Jefferies Global Healthcare Conference on November 17 at 5:00 pm GMT (12:00 pm ET)
- Piper Sandler Healthcare Conference on December 1 at 11:00 am ET
The live webcasts can be accessed on the Investors & Media page of Cogent’s website at investors.cogentbio.com/events. A replay will be available approximately two hours after completion of each event and will be archived for up to 30 days.
Third Quarter 2026 Financial Results
Cash Position: As of September 30, 2026, cash, cash equivalents and marketable securities were
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Net Loss: Net loss was
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving Systemic Mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced Gastrointestinal Stromal Tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: potential FDA approval and commercial launch of bezuclastinib in GIST; potential FDA approval of bezuclastinib in both NonAdvSM and AdvSM; cash runway expected to fund operations into late 2028 and well past all three pending PDUFA action dates for bezuclastinib; plans to submit INDs for the company’s JAK2 and KRAS pipeline programs and to move into clinical development soon; plans to complete dose escalation for CGT4255; and plans to present multiple poster presentations featuring bezuclastinib at ASH 2026 and the contents of those presentations. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Quarterly Report on Form 10-Q filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
| COGENT BIOSCIENCES, INC. | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (in thousands) | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 75,099 | $ | 68,989 | $ | 221,275 | $ | 194,221 | |||||||
| General and administrative | 42,085 | 14,366 | 102,154 | 39,649 | |||||||||||
| Total operating expenses | 117,184 | 83,355 | 323,429 | 233,870 | |||||||||||
| Loss from operations | (117,184 | ) | (83,355 | ) | (323,429 | ) | (233,870 | ) | |||||||
| Other income: | |||||||||||||||
| Interest income | 7,052 | 3,887 | 22,121 | 9,212 | |||||||||||
| Interest expense | (1,243 | ) | (1,459 | ) | (3,673 | ) | (1,773 | ) | |||||||
| Other expense, net | (51 | ) | (3 | ) | (202 | ) | (14 | ) | |||||||
| Total other income, net | 5,758 | 2,425 | 18,246 | 7,425 | |||||||||||
| Net loss | $ | (111,426 | ) | $ | (80,930 | ) | $ | (305,183 | ) | $ | (226,445 | ) | |||
| COGENT BIOSCIENCES, INC. | ||||||||
| SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA | ||||||||
| (in thousands) | ||||||||
| (unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Cash, cash equivalents and marketable securities | $ | 791,134 | $ | 900,765 | ||||
| Working capital | $ | 730,466 | $ | 846,402 | ||||
| Total assets | $ | 832,142 | $ | 937,607 | ||||
| Total liabilities | $ | 315,884 | $ | 301,236 | ||||
| Total stockholders’ equity | $ | 516,258 | $ | 636,371 | ||||
Contact: Christi Waarich Senior Director, Investor Relations christi.waarich@cogentbio.com 617-830-1653
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When are Cogent’s bezuclastinib FDA target action dates?
Bezuclastinib’s FDA target action dates are November 30, 2026 for GIST, December 30, 2026 for NonAdvanced Systemic Mastocytosis and June 29, 2027 for Advanced Systemic Mastocytosis. These are dates for potential approval decisions, not completed approvals.
How long does Cogent expect its cash to last?
Cogent expects its cash, cash equivalents and marketable securities to fund operating expenses and capital expenditure requirements into late 2028. Those resources totaled $791.1 million at September 30, 2026, compared with $792.3 million at June 30, 2026.
What will Cogent’s new PEAK extension cohort study?
The single-arm, 40-patient PEAK extension cohort will investigate bezuclastinib combined with sunitinib in first-line GIST patients. It is designed to measure objective response rate, the proportion of patients whose tumors shrink, and progression-free survival, time without disease worsening, in patients with exon 9 or exon 11 primary mutations.
What bezuclastinib results does Cogent plan to present at ASH 2026?
Cogent plans to present additional SUMMIT analyses and the first clinical results from a sub-study of patients switching from avapritinib to bezuclastinib at ASH, December 12–15, 2026. Presentations will address skin and neurocognitive symptoms, longer-term disease-biology follow-up, and a comparison of symptom burden in NonAdvanced Systemic Mastocytosis patients with the general population.